Sign in Subscribe

Alex Chompff

Oral TKI anlotinib shows non-inferiority to bevacizumab plus chemotherapy in first-line RAS/BRAF wild-type metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Oral TKI anlotinib shows non-inferiority to bevacizumab plus chemotherapy in first-line RAS/BRAF wild-type metastatic colorectal cancer The phase 3 ANCHOR trial (NCT04854668) compared CapeOX chemotherapy combined with anlotinib versus CapeOX combined with bevacizumab in patients with RAS/BRAF wild-type mCRC, evaluating

CRC Research Update — August 31, 2026

Today's colorectal cancer research highlights

Plant-derived formulation disrupts metabolism in KRAS-mutant colorectal and pancreatic cancer cells

Skip to content The CRC Digest Plant-derived formulation disrupts metabolism in KRAS-mutant colorectal and pancreatic cancer cells A Lepidium latifolium formulation induced cell death and metabolic disruption in KRAS-mutant cancer models through iron-dependent mechanisms. (Molecules) This content is informational only and does not constitute medical advice. Always consult your oncologist

Roadmap for early-onset colorectal cancer prevention highlights lifestyle factors and emerging risk pathways

Skip to content The CRC Digest Roadmap for early-onset colorectal cancer prevention highlights lifestyle factors and emerging risk pathways Review identifies obesity, metabolic conditions, poor diet, and sedentary behavior as key EOCRC risk factors, with growing evidence for early-life and gut microbial exposures. (Nature Reviews Cancer) This content is informational

Study evaluates potential hearing damage from oxaliplatin in preclinical model

Skip to content The CRC Digest ♥ LIVING WITH CRC Study evaluates potential hearing damage from oxaliplatin in preclinical model Mouse study evaluated potential hearing damage induced by oxaliplatin. (Hearing Research) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The

NF-κB/Lipocalin 2 pathway may reduce chemoresistance in BRAF-mutant colorectal cancer by promoting ferroptosis

Skip to content The CRC Digest ◇ RESEARCH NF-κB/Lipocalin 2 pathway may reduce chemoresistance in BRAF-mutant colorectal cancer by promoting ferroptosis Preclinical research found that the NF-κB/LCN2 signaling pathway enhances cisplatin sensitivity in BRAF V600E-mutant CRC cells through iron-dependent cell death. (Cancers) This content is informational only and does

Immunotherapy produces durable responses in dMMR/MSI-H metastatic colorectal cancer patients with poor performance status

Skip to content The CRC Digest ▸ TREATMENT Immunotherapy produces durable responses in dMMR/MSI-H metastatic colorectal cancer patients with poor performance status Patients with dMMR/MSI-H tumors who had poor performance status still achieved durable responses to immunotherapy, expanding treatment options for this vulnerable group. (Clinical Colorectal Cancer) This content

Phase III trial shows circulating tumor DNA methylation monitoring can guide postoperative surveillance in nonmetastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Phase III trial shows circulating tumor DNA methylation monitoring can guide postoperative surveillance in nonmetastatic colorectal cancer The prospective, randomized FIND trial used dynamic ctDNA methylation monitoring to personalize follow-up care after surgery in stage I-III patients. (Journal of Clinical Oncology) This

CRC Research Update — August 30, 2026

Today's colorectal cancer research highlights

Genomic Differences Between Early-Onset and Average-Onset Metastatic CRC Identified

Skip to content The CRC Digest ◇ RESEARCH Genomic Differences Between Early-Onset and Average-Onset Metastatic CRC Identified A real-world next-generation sequencing study compared the genomic landscape of early-onset colorectal cancer with average-onset metastatic disease, identifying distinct molecular features in younger patients. (JCO Precision Oncology) This content is informational only and does